Introduction And Pathophysiology

• Most common inherited bleeding disorder.
• Prevalence: Biochemical evidence in 1-2% of population; symptomatic in 0.1%.
• Caused by quantitative deficiency or qualitative dysfunction of von Willebrand factor (vWF).
• Dual physiologic functions of vWF:
  • Tethers platelets to injured subendothelium via collagen and platelet glycoprotein Ib (GPIb) receptors.
  • Chaperone protein for Factor VIII (FVIII); protects FVIII from premature plasma protease degradation.
• Synthesized in megakaryocytes and endothelial cells.
• Stored intracellularly in endothelial Weibel-Palade bodies and platelet alpha-granules.
• Circulates as large multimeric glycoprotein; high-molecular-weight (HMW) multimers dictate hemostatic efficacy.
• Endothelial shear stress induces conformational uncoiling, facilitating platelet binding.

Clinical Manifestations

• Predominantly mucocutaneous hemorrhage.
• Common symptoms: Epistaxis, easy bruising, gingival bleeding, menorrhagia.
• Prolonged bleeding post-trauma or surgery (adenotonsillectomy, dental extraction).
• Severe forms (Type 3) manifest deep tissue, joint, and muscle hemorrhages mimicking severe hemophilia.
• Gastrointestinal hemorrhage may occur, frequently complicated by intestinal angiodysplastic lesions.
• Variable expressivity and incomplete penetrance observed across families.

Classification And Genetic Characteristics

Special Variants And Modifying Factors

Acquired Von Willebrand Syndrome

• Rare non-inherited reduction in vWF.
• Mechanisms: Autoantibodies, adsorption onto malignant cells, or depletion via high vascular shear forces.
• Associated conditions: Wilms tumor, congenital heart defects (high-flow lesions), hypothyroidism, systemic lupus erythematosus (SLE), myeloproliferative neoplasms.

Physiologic Modifiers Of Von Willebrand Factor

• Blood Group O: Associated with 25-30% lower baseline vWF levels.
• Elevating Factors: Stress, systemic inflammation, vigorous exercise, menstrual cycle fluctuations, pregnancy, estrogen supplementation.
• Depressing Factors: Valproic acid, hypothyroidism.
• Dynamic nature necessitates repeated testing for definitive diagnosis.

Diagnostic Evaluation

Primary Screening Tests

• Complete Blood Count: Usually normal. Mild thrombocytopenia specifically suggests Type 2B or Platelet-Type pseudo-vWD.
• Activated Partial Thromboplastin Time (aPTT): Normal or mildly prolonged depending on concurrent FVIII degradation.
• Prothrombin Time (PT): Normal.
• Platelet Function Analyzer (PFA-100): Closure time prolonged (collagen/epinephrine or collagen/ADP); lacks absolute sensitivity.
• Bleeding Time: Historically prolonged; currently obsolete due to poor reproducibility.

Specific Von Willebrand Panel

• vWF Antigen (vWF:Ag): Quantifies total plasma vWF protein. Levels <30 IU/dL establish definitive diagnosis. Levels 30-50 IU/dL designated "low vWF".
• vWF Ristocetin Cofactor Activity (vWF:RCo): Assesses functional vWF-platelet interaction mediated by ristocetin.
• vWF:GPIbM: Improved functional assay evaluating spontaneous GPIb binding without ristocetin requirement.
• Factor VIII Activity (FVIII:C): Quantifies circulating FVIII. Markedly reduced in Type 2N and Type 3.
• vWF Activity/Antigen Ratio (vWF:RCo / vWF:Ag): Ratio <0.7 indicates qualitative dysfunction, strongly suggesting Type 2A, 2B, or 2M.
• vWF Multimer Analysis: Visualizes molecular weight distribution. Differentiates subtypes based on absence of HMW multimers.
• Ristocetin-Induced Platelet Aggregation (RIPA): Utilizing low-dose ristocetin. Enhanced aggregation specifically identifies Type 2B and Platelet-Type pseudo-vWD.

Management Strategies

Desmopressin (DDAVP)

• Mechanism: Synthetic vasopressin analog. Induces endothelial cell Weibel-Palade body degranulation. Endogenous vWF and FVIII plasma levels increase twofold to fivefold.
• Indications: First-line therapy for Type 1. Effective for mild bleeding or minor surgery.
• Contraindications: Type 2B (exacerbates thrombocytopenia/agglutination), Type 3 (no endothelial stores), neonates <2 years (hyponatremic seizure risk).
• Administration: Intravenous 0.3 $\mu$g/kg (max 20-30 $\mu$g/day) or highly concentrated intranasal spray (Stimate 1.5 mg/mL: 150 $\mu$g for <50 kg; 300 $\mu$g for >50 kg).
• Limitations: Tachyphylaxis develops after 4-5 consecutive days. Therapeutic trial mandatory prior to major procedures to confirm individual responsiveness.
• Adverse Effects: Facial flushing, mild fluid retention, hyponatremia. Restrict free water intake.

Component Replacement Therapy

• Products: Plasma-derived, virally-inactivated FVIII/vWF concentrates (e.g., Humate-P, Alphanate, Wilate) or recombinant vWF (Vonvendi).
• Indications: Type 3 disease, severe Type 1, Type 1C (clearance defect), Type 2 variants, DDAVP non-responders, or major surgical interventions.
• Dosing: 40-60 Ristocetin Cofactor Activity (RCo) units/kg. Adjusted based on baseline vWF level and target peak.
• Monitoring: Track FVIII levels closely during repeated dosing. Sustained FVIII >150 IU/dL increases venous thromboembolism risk.

Adjunctive Therapies

• Antifibrinolytics: Epsilon-aminocaproic acid (50-100 mg/kg PO/IV q6h) or Tranexamic acid (1300 mg PO tid). Stabilizes mucosal clots. Essential for dental extractions, epistaxis, and oropharyngeal hemorrhage.
• Hormonal Therapy: Oral contraceptives, depot medroxyprogesterone, or levonorgestrel intrauterine devices (Mirena). First-line management for severe menorrhagia.
• Topical Hemostatics: Nasal cautery, petrolatum gauze packing, local pressure application.

Treatment Algorithm By Bleeding Severity